Jump Financial LLC Invests $1.67 Million in Ascendis Pharma A/S (NASDAQ:ASND)

Jump Financial LLC purchased a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND) in the 4th quarter, HoldingsChannel.com reports. The fund purchased 12,105 shares of the biotechnology company’s stock, valued at approximately $1,666,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Artisan Partners Limited Partnership raised its holdings in shares of Ascendis Pharma A/S by 0.9% during the fourth quarter. Artisan Partners Limited Partnership now owns 4,450,420 shares of the biotechnology company’s stock valued at $612,689,000 after acquiring an additional 39,309 shares during the last quarter. FIL Ltd raised its stake in Ascendis Pharma A/S by 13.9% in the 4th quarter. FIL Ltd now owns 729,275 shares of the biotechnology company’s stock valued at $100,399,000 after purchasing an additional 89,016 shares during the last quarter. American Century Companies Inc. lifted its holdings in Ascendis Pharma A/S by 17.5% in the 4th quarter. American Century Companies Inc. now owns 407,294 shares of the biotechnology company’s stock valued at $56,072,000 after purchasing an additional 60,548 shares in the last quarter. ARS Investment Partners LLC boosted its stake in Ascendis Pharma A/S by 0.9% during the 4th quarter. ARS Investment Partners LLC now owns 265,480 shares of the biotechnology company’s stock worth $36,549,000 after purchasing an additional 2,369 shares during the last quarter. Finally, New York State Common Retirement Fund raised its position in shares of Ascendis Pharma A/S by 14.0% in the fourth quarter. New York State Common Retirement Fund now owns 204,482 shares of the biotechnology company’s stock valued at $28,151,000 after buying an additional 25,164 shares during the last quarter.

Ascendis Pharma A/S Stock Performance

Shares of ASND stock opened at $165.05 on Friday. Ascendis Pharma A/S has a fifty-two week low of $111.09 and a fifty-two week high of $169.37. The company has a 50 day moving average price of $152.00 and a 200 day moving average price of $138.14. The stock has a market capitalization of $10.06 billion, a P/E ratio of -23.25 and a beta of 0.54.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($1.32) by $0.64. On average, research analysts forecast that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on ASND. UBS Group assumed coverage on shares of Ascendis Pharma A/S in a research report on Tuesday, January 7th. They set a “buy” rating and a $196.00 price target on the stock. JPMorgan Chase & Co. lifted their price objective on Ascendis Pharma A/S from $168.00 to $200.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 18th. The Goldman Sachs Group raised their target price on Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a “buy” rating in a research note on Thursday, February 13th. Evercore ISI upped their price objective on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an “outperform” rating in a report on Tuesday, February 18th. Finally, Morgan Stanley set a $180.00 price target on shares of Ascendis Pharma A/S in a research note on Tuesday, February 18th. Two investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $204.67.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.